Tempus AI (NASDAQ:TEM) CEO Ryan Fukushima Sells 20,000 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Ryan Fukushima sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $50.04, for a total transaction of $1,000,800.00. Following the sale, the chief executive officer directly owned 123,945 shares in the company, valued at $6,202,207.80. The trade was a 13.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Fukushima also recently made the following trade(s):

• On Monday, August 3rd, Ryan Fukushima sold 23,818 shares of Tempus AI stock. The shares were sold at an average price of $46.19, for a total transaction of $1,100,153.42.
• On Wednesday, July 8th, Ryan Fukushima sold 33,284 shares of Tempus AI stock. The shares were sold at an average price of $57.39, for a total transaction of $1,910,168.76.
• On Monday, July 6th, Ryan Fukushima sold 10,000 shares of Tempus AI stock. The stock was sold at an average price of $60.00, for a total transaction of $600,000.00.
• On Tuesday, May 19th, Ryan Fukushima sold 13,550 shares of Tempus AI stock. The shares were sold at an average price of $44.07, for a total value of $597,148.50.

Tempus AI Stock Up 1.1%

Shares of NASDAQ:TEM opened at $55.69 on Wednesday. The firm has a market cap of $10.05 billion, a P/E ratio of -38.67 and a beta of 3.58. Tempus AI, Inc. has a 12-month low of $40.77 and a 12-month high of $104.32. The business has a fifty day simple moving average of $51.49 and a 200 day simple moving average of $51.68. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. The firm had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The business’s revenue was up 21.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.22) EPS. Analysts predict that Tempus AI, Inc. will post -1.38 earnings per share for the current year.

Hedge Funds Weigh In On Tempus AI

Several institutional investors have recently added to or reduced their stakes in the business. GC Wealth Management RIA LLC bought a new stake in Tempus AI in the fourth quarter valued at $399,267,000. Voloridge Investment Management LLC raised its holdings in shares of Tempus AI by 183.0% during the third quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock valued at $129,708,000 after purchasing an additional 1,039,176 shares during the period. AQR Capital Management LLC bought a new position in shares of Tempus AI during the 2nd quarter worth about $54,020,000. Amova Asset Management Americas Inc. boosted its position in shares of Tempus AI by 23.4% during the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock worth $195,549,000 after purchasing an additional 821,490 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Tempus AI by 23.4% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after buying an additional 821,490 shares during the period. 24.22% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on TEM shares. Freedom Capital raised shares of Tempus AI to a “hold” rating in a research report on Tuesday, June 30th. Needham & Company LLC reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Tempus AI in a research note on Friday, July 31st. Piper Sandler decreased their price objective on shares of Tempus AI from $58.00 to $56.00 and set a “neutral” rating for the company in a research report on Tuesday, August 4th. TD Cowen reissued a “buy” rating on shares of Tempus AI in a research note on Wednesday, July 15th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Tempus AI in a report on Wednesday, June 17th. Nine research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Tempus AI has a consensus rating of “Hold” and a consensus price target of $64.92.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.